Industry
KFF Analysis Examines Why Drug Prices Dominate Policy Debate Over Hospital Costs
KFF's Larry Levitt published a JAMA Health Forum post identifying four reasons why high drug prices receive more policy attention than hospital prices, despite hospitals accounting for 40% of national health spending growth from 2022 to 2024. The analysis explores barriers to hospital price restraint and potential policy interventions. The post provides context for understanding the political economy of health care cost containment efforts. No immediate policy changes are announced.
Why it mattersMedicaid managed care organizations face increasing hospital price pressure with limited policy tools for rate negotiation, while pharmaceutical cost controls receive disproportionate legislative focus despite hospitals driving larger share of spending growth.